Sabatino Marianna, Stroncek David F, Klein Harvey, Marincola Francesco M, Wang Ena
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10 Room 1C711, Bethesda, MD 20892, United States.
Cancer Lett. 2009 Jul 8;279(2):119-25. doi: 10.1016/j.canlet.2008.10.039. Epub 2008 Dec 17.
Cutaneous melanoma is a significant health problem worldwide. Available treatments can induce objective tumor regression in a small percent of patients, but these responses are not always associated with improved long-term survival. The resistance of melanoma to therapy and its predestined recurrence are related to the genetic heterogeneity and genomic instability of the tumor. For many years these genetic alterations were thought to be linked to the accumulation of random mutations in functionally differentiated cells which transform them into malignant cells that have lost their ability to differentiate and have acquired drug resistance. In the last few years it has been largely demonstrated that melanoma as other solid tumors contains a subpopulation of cells (CSCs) considered the source of the primary tumor mass, of new tumor nodules and responsible for drug resistance and cancer recurrence. In this review, we provide an overview of findings and advances in CSCs research that are relevant to the initiation, natural history, and the response to treatment of malignant melanoma.
皮肤黑色素瘤是全球范围内一个重大的健康问题。现有的治疗方法能使一小部分患者出现客观的肿瘤消退,但这些反应并不总是与长期生存率的提高相关。黑色素瘤对治疗的抗性及其注定的复发与肿瘤的基因异质性和基因组不稳定性有关。多年来,这些基因改变被认为与功能分化细胞中随机突变的积累有关,这些突变将它们转化为失去分化能力并获得耐药性的恶性细胞。在过去几年中,大量研究表明,与其他实体瘤一样,黑色素瘤含有一群细胞(癌症干细胞),被认为是原发肿瘤块、新肿瘤结节的来源,也是耐药性和癌症复发的原因。在这篇综述中,我们概述了与恶性黑色素瘤的发生、自然病程及治疗反应相关的癌症干细胞研究的发现和进展。